Teladoc, Inc. (NYSE:TDOC)‘s stock had its “hold” rating restated by equities researchers at Cantor Fitzgerald in a research report issued on Tuesday. They currently have a $31.00 price objective on the health services provider’s stock. Cantor Fitzgerald’s price target would indicate a potential downside of 1.59% from the company’s previous close.

The analysts wrote, “Management indicates a high confidence level that the newly-expanded relationship (shared savings with no PMPM) with Aetna will help to grow revenue and earnings over time.””

Several other research firms have also issued reports on TDOC. Cowen and Company reissued an “outperform” rating and set a $39.00 price target (up previously from $36.00) on shares of Teladoc in a report on Thursday, August 3rd. Piper Jaffray Companies reissued a “buy” rating and set a $32.00 price target on shares of Teladoc in a report on Friday, July 14th. TheStreet lowered Teladoc from a “c-” rating to a “d” rating in a report on Monday, July 3rd. BidaskClub lowered Teladoc from a “buy” rating to a “hold” rating in a report on Tuesday, July 25th. Finally, William Blair reissued an “outperform” rating on shares of Teladoc in a report on Tuesday, June 20th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $36.18.

Teladoc (NYSE:TDOC) opened at 31.35 on Tuesday. The firm has a 50-day moving average price of $34.32 and a 200 day moving average price of $34.32. Teladoc has a 52 week low of $14.00 and a 52 week high of $37.55. The company’s market cap is $1.78 billion.

Teladoc (NYSE:TDOC) last released its quarterly earnings results on Wednesday, August 2nd. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.02). Teladoc had a negative net margin of 47.75% and a negative return on equity of 19.88%. The company had revenue of $44.60 million for the quarter, compared to the consensus estimate of $44.39 million. During the same period in the prior year, the firm posted ($0.38) EPS. The business’s revenue for the quarter was up 68.3% on a year-over-year basis. Analysts expect that Teladoc will post ($1.44) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/28/teladoc-inc-tdoc-stock-rating-reaffirmed-by-cantor-fitzgerald.html.

In related news, insider Adam C. Vandervoort sold 53,806 shares of the business’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.92, for a total value of $1,663,681.52. Following the sale, the insider now directly owns 33,008 shares in the company, valued at $1,020,607.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Mark Hirschhorn sold 25,000 shares of the business’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $31.93, for a total value of $798,250.00. Following the completion of the sale, the vice president now owns 64,987 shares in the company, valued at $2,075,034.91. The disclosure for this sale can be found here. Corporate insiders own 4.47% of the company’s stock.

Several large investors have recently bought and sold shares of TDOC. FMR LLC lifted its position in shares of Teladoc by 163.5% in the first quarter. FMR LLC now owns 8,103,237 shares of the health services provider’s stock worth $202,581,000 after buying an additional 5,028,237 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of Teladoc in the second quarter worth about $58,287,000. JPMorgan Chase & Co. lifted its position in shares of Teladoc by 8,826.7% in the first quarter. JPMorgan Chase & Co. now owns 1,606,535 shares of the health services provider’s stock worth $40,163,000 after buying an additional 1,588,538 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Teladoc by 211.1% in the first quarter. Alliancebernstein L.P. now owns 2,286,200 shares of the health services provider’s stock worth $57,155,000 after buying an additional 1,551,315 shares in the last quarter. Finally, Janus Capital Management LLC purchased a new stake in shares of Teladoc in the first quarter worth about $37,258,000.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.